Janssen Inc. v. Apotex Inc.

JurisdictionFederal Jurisdiction (Canada)
CourtFederal Court (Canada)
Citation2022 FC 996
Date06 July 2022

Get this document and AI-powered insights with a free trial of vLex and Vincent AI

Get Started for Free

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex
4 practice notes
  • 2022 Year In Review: IP Litigation
    • Canada
    • Mondaq Canada
    • March 7, 2023
    ...a generic drug manufacturer is said to induce prescribing physicians (Janssen Inc v Apotex Inc, 2022 FC 107; Janssen Inc v Apotex Inc, 2022 FC 996; and Janssen Inc v Pharmascience, 2022 FC 62). Similarly, in UPL NA Inc v AgraCity Crop & Nutrition Ltd, 2022 FC 1422, an action for patent infr......
  • Apotex Inc. v. Janssen Inc.
    • Canada
    • Court of Appeal (Canada)
    • November 9, 2023
    ...In an action pursuant to the Patented Medicines (Notice of Compliance) Regulations, S.O.R./93-133 (the Regulations), the Federal Court (2022 FC 996, per Justice Christine M. Pallotta) agreed with the respondents’ allegation and enjoined Apotex from various activities involving Apo-Macitenta......
  • Canadian Patent Law: 2022 Year In Review
    • Canada
    • Mondaq Canada
    • January 17, 2023
    ...the claimed subject matter was not obvious to try and Pharmascience's obviousness defence failed. The decision of Janssen v Apotex, ( 2022 FC 996) related to infringement via inducement. The patent at issue claimed, generally speaking, the use of the active ingredient macitentan in combinat......
  • Janssen Succeeds On Infringement Against Apotex In Macitentan Combination Patent Case
    • Canada
    • Mondaq Canada
    • July 21, 2022
    ...Apotex would infringe Janssen's patent relating to Janssen's OPSUMIT (macitentan) by selling APO-MACITENTAN: Janssen Inc v Apotex Inc, 2022 FC 996. Apotex did not challenge Canadian Patent No. 2,659,770 (770 Patent) was the subject of an earlier s. 6(1) action involving Janssen and Sandoz, ......
1 cases
  • Apotex Inc. v. Janssen Inc.
    • Canada
    • Court of Appeal (Canada)
    • November 9, 2023
    ...In an action pursuant to the Patented Medicines (Notice of Compliance) Regulations, S.O.R./93-133 (the Regulations), the Federal Court (2022 FC 996, per Justice Christine M. Pallotta) agreed with the respondents’ allegation and enjoined Apotex from various activities involving Apo-Macitenta......
3 firm's commentaries
  • 2022 Year In Review: IP Litigation
    • Canada
    • Mondaq Canada
    • March 7, 2023
    ...a generic drug manufacturer is said to induce prescribing physicians (Janssen Inc v Apotex Inc, 2022 FC 107; Janssen Inc v Apotex Inc, 2022 FC 996; and Janssen Inc v Pharmascience, 2022 FC 62). Similarly, in UPL NA Inc v AgraCity Crop & Nutrition Ltd, 2022 FC 1422, an action for patent infr......
  • Canadian Patent Law: 2022 Year In Review
    • Canada
    • Mondaq Canada
    • January 17, 2023
    ...the claimed subject matter was not obvious to try and Pharmascience's obviousness defence failed. The decision of Janssen v Apotex, ( 2022 FC 996) related to infringement via inducement. The patent at issue claimed, generally speaking, the use of the active ingredient macitentan in combinat......
  • Janssen Succeeds On Infringement Against Apotex In Macitentan Combination Patent Case
    • Canada
    • Mondaq Canada
    • July 21, 2022
    ...Apotex would infringe Janssen's patent relating to Janssen's OPSUMIT (macitentan) by selling APO-MACITENTAN: Janssen Inc v Apotex Inc, 2022 FC 996. Apotex did not challenge Canadian Patent No. 2,659,770 (770 Patent) was the subject of an earlier s. 6(1) action involving Janssen and Sandoz, ......